Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill breast cancer cells. Phase II trial to study the effectiveness of trastuzumab plus interleukin-2 in treating patients who have metastatic breast cancer that has not responded to previous trastuzumab therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To estimate the response rate and toxicity to low-dose IL-2 with intermediate-"pulse" dose interleukin 2 (IL-2) and trastuzumab in patients with uni-dimensional measurable metastatic breast cancer and human epidermal growth factor receptor 2 (HER2) positive (3+ overexpression by immunohistochemistry \[IHC\] method or positive by fluorescent in situ hybridization \[FISH\]) who either have had evidence of progressive disease while receiving a trastuzumab-containing regimen, or have had progressive disease within 12 months of receiving a trastuzumab-containing regimen.

SECONDARY OBJECTIVES:

I. To perform correlative immunologic assays to determine the degree of natural killer (NK) cell expansion in response to low-dose IL-2, and the effectiveness of patients' peripheral blood mononuclear cells (PBMC) in a standard antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed against a HER2 target cell.

II. To determine the pharmacokinetics of trastuzumab using an every 2-week schedule.

III. To determine Fc-gamma receptor polymorphisms from study patients.

OUTLINE: This is a multicenter study.

Patients receive trastuzumab intravenously (IV) over 30-90 minutes on days 1 and 8 and aldesleukin subcutaneously (SC) on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for at least 30 days.

PROJECTED ACCRUAL: A total of 17-37 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (trastuzumab and aldesleukin)

Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

trastuzumab

Intervention Type BIOLOGICAL

Given IV

aldesleukin

Intervention Type BIOLOGICAL

Given SC

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

pharmacological study

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

trastuzumab

Given IV

Intervention Type BIOLOGICAL

aldesleukin

Given SC

Intervention Type BIOLOGICAL

laboratory biomarker analysis

Correlative studies

Intervention Type OTHER

pharmacological study

Correlative studies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed breast cancer

* Primary and/or metastatic disease
* HER2 overexpression 3+ by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH)

* Tumors with HER2 2+ overexpression by IHC allowed if confirmed by FISH
* Progressive disease during or within 12 months of receiving prior regimen containing trastuzumab (Herceptin)
* Unidimensionally measurable disease

* At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
* The following are not considered measurable:

* Bone metastases
* Pleural or peritoneal effusion
* Ascites
* Leptomeningeal disease
* Lymphangitic disease
* Inflammatory breast cancer
* Cystic lesions
* CNS lesions
* CNS metastases allowed if all of the following conditions are met:

* Asymptomatic
* At least 3 months since prior surgery and/or cranial irradiation
* At least 3 weeks since prior steroids
* Hormone receptor status:

* Not specified
* Male or female
* Performance status - ECOG 0-2
* Granulocyte count at least 1,000/mm\^3
* Platelet count at least 100,000/mm\^3
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* SGOT and SGPT no greater than 2 times ULN (5 times ULN for liver metastases)
* Alkaline phosphatase no greater than 2 times ULN (5 times ULN for liver metastases)
* Creatinine no greater than 1.5 times ULN
* LVEF at least lower limit of normal by MUGA or echocardiogram
* No congestive heart failure or active ischemic heart disease
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No psychiatric illness, medical condition, or uncontrolled infection that would preclude study
* No underlying immunodeficiency (e.g., HIV or autoimmune disease)
* No other prior malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
* See Disease Characteristics
* Prior cumulative doxorubicin dose no greater than 360 mg/m\^2
* At least 3 weeks since prior chemotherapy
* No more than 2 prior chemotherapy regimens for metastatic disease
* No concurrent chemotherapy
* See Disease Characteristics
* At least 3 weeks since prior endocrine therapy
* No concurrent corticosteroids or dexamethasone
* Concurrent hormones allowed for conditions unrelated to disease (e.g., insulin for diabetes)
* See Disease Characteristics
* At least 3 weeks since prior radiotherapy
* No prior radiotherapy to study lesion, unless evidence of disease progression
* No concurrent palliative radiotherapy
* See Disease Characteristics
* At least 4 weeks since prior major surgery
* No concurrent immunosuppressive drugs

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Charles Shapiro

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ohio State University Medical Center

Columbus, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States